Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lyell Immunopharma, Inc. - Common Stock
(NQ:
LYEL
)
36.05
+0.96 (+2.74%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lyell Immunopharma, Inc. - Common Stock
< Previous
1
2
Next >
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
December 24, 2025
Issued on behalf of GT Biopharma, Inc.
From
Equity Insider
Via
GlobeNewswire
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
December 07, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
November 12, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
November 10, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
November 03, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
September 03, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces Participation in September Investor Conferences
September 02, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
August 12, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces up to $100 Million Equity Private Placement
July 25, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
June 23, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
June 17, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
June 09, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
June 04, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025
May 13, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025
May 01, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
April 15, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
March 11, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
February 18, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
January 09, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
December 09, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
November 07, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
November 05, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
October 31, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
October 24, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 04, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
September 24, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces Participation in September Investor Conferences
August 28, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
August 07, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
June 26, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
June 03, 2024
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
